Incyte (INCY) Current Leases (2018 - 2026)
Incyte's (INCY) quarterly Current Leases came in at $4.3 million in Q2 2026, down 4.83% YoY from $4.5 million in Q2 2025, and down 3.49% on a QoQ basis from $4.4 million in Q1 2026.
Incyte (INCY) Current Leases (2018 - 2026) Analysis & Trends
Incyte (INCY) has 9 years of Current Leases data on file, last reported at $4.3 million in Q2 2026.
- Quarterly Current Leases fell 4.83% year-over-year to $4.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $4.3 million (down 4.83% YoY) and the FY2025 annual result came in at $4.5 million, up 2.2% from the prior year.
- Current Leases retreated to $4.3 million in Q2 2026, from $4.4 million in the prior quarter.
- In the past five years, Current Leases ranged from a high of $9.9 million in Q1 2022 to a low of $3.1 million in Q3 2023.
- A 5-year average of $4.5 million and a median of $4.1 million in 2024 frame the typical range for Current Leases.
- Annual changes were most pronounced in 2022 — Current Leases tumbled 68.4% — and 2024, when it increased 28.5%.
- Tracing INCY's Current Leases over 5 years: stood at $3.2 million in 2022, then advanced by 8.18% to $3.4 million in 2023, then advanced by 28.5% to $4.4 million in 2024, then grew by 2.2% to $4.5 million in 2025, then declined by 5.69% to $4.3 million in 2026.
- The last three Current Leases figures came in at $4.3 million (Q2 2026), $4.4 million (Q1 2026), and $4.5 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Incyte | 24.15 Bn | 19.61 Bn | 1.57 Bn | 4.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.26 Mn |
| Mar 31, 2026 | 4.41 Mn |
| Dec 31, 2025 | 4.52 Mn |
| Sep 30, 2025 | 4.49 Mn |
| Jun 30, 2025 | 4.48 Mn |
| Mar 31, 2025 | 4.48 Mn |
| Dec 31, 2024 | 4.42 Mn |
| Sep 30, 2024 | 3.93 Mn |
| Jun 30, 2024 | 3.87 Mn |
| Mar 31, 2024 | 3.68 Mn |
| Dec 31, 2023 | 3.44 Mn |
| Sep 30, 2023 | 3.06 Mn |
| Jun 30, 2023 | 3.17 Mn |
| Mar 31, 2023 | 3.15 Mn |
| Dec 31, 2022 | 3.18 Mn |
| Sep 30, 2022 | 3.11 Mn |
| Jun 30, 2022 | 9.37 Mn |
| Mar 31, 2022 | 9.90 Mn |
| Dec 31, 2021 | 2.64 Mn |
| Sep 30, 2021 | 9.85 Mn |